Literature DB >> 20541836

Cannabis-based medicines in multiple sclerosis--a review of clinical studies.

David J Rog1.   

Abstract

For some years a mixture of anecdotal report and data from animal models have implied a potential role for cannabis-based medicines in ameliorating a variety of symptoms of multiple sclerosis. Only recently however have large randomised controlled trials (RCTs) examined these potential effects rigorously. At present the results of RCTs have lacked a coherent message to the prescribing clinician and reasons for such heterogeneity in cannabinoid trials are discussed. 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20541836     DOI： 10.1016/j.imbio.2010.03.009

Source DB:  PubMed          Journal:  Immunobiology        ISSN： 0171-2985            Impact factor:   3.144


  13 in total

1.  Receptors: cannabis medicine without a high.

Authors:  Macdonald J Christie; Christopher W Vaughan
Journal:  Nat Chem Biol       Date:  2011-05       Impact factor: 15.040

Review 2.  The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.

Authors:  A Tubaro; F Puccini; C De Nunzio; G A Digesu; S Elneil; C Gobbi; V Khullar
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

3.  Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.

Authors:  Verena Isabell Leussink; Leila Husseini; Clemens Warnke; Erasmia Broussalis; Hans-Peter Hartung; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2012-09       Impact factor: 6.570

4.  Activation of type-2 cannabinoid receptor inhibits neuroprotective and antiinflammatory actions of glucocorticoid receptor α: when one is better than two.

Authors:  Elisa Bisicchia; Valerio Chiurchiù; Maria Teresa Viscomi; Laura Latini; Filomena Fezza; Luca Battistini; Mauro Maccarrone; Marco Molinari
Journal:  Cell Mol Life Sci       Date:  2013-01-08       Impact factor: 9.261

Review 5.  [Cannabinoids for symptomatic therapy of multiple sclerosis].

Authors:  L Husseini; V I Leussink; C Warnke; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

6.  Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Authors:  Serena Deiana; Akihito Watanabe; Yuki Yamasaki; Naoki Amada; Marlene Arthur; Shona Fleming; Hilary Woodcock; Patricia Dorward; Barbara Pigliacampo; Steve Close; Bettina Platt; Gernot Riedel
Journal:  Psychopharmacology (Berl)       Date:  2011-07-28       Impact factor: 4.530

7.  Epigenetic control of skin differentiation genes by phytocannabinoids.

Authors:  Mariangela Pucci; Cinzia Rapino; Andrea Di Francesco; Enrico Dainese; Claudio D'Addario; Mauro Maccarrone
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

8.  Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells.

Authors:  L Jean-Gilles; M Braitch; M L Latif; J Aram; A J Fahey; L J Edwards; R A Robins; R Tanasescu; P J Tighe; B Gran; L C Showe; S P Alexander; V Chapman; D A Kendall; C S Constantinescu
Journal:  Acta Physiol (Oxf)       Date:  2015-03-10       Impact factor: 6.311

Review 9.  Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.

Authors:  Debra A Kendall; Guillermo A Yudowski
Journal:  Front Cell Neurosci       Date:  2017-01-04       Impact factor: 5.505

10.  Compromised External Validity: Federally Produced Cannabis Does Not Reflect Legal Markets.

Authors:  Daniela Vergara; L Cinnamon Bidwell; Reggie Gaudino; Anthony Torres; Gary Du; Travis C Ruthenburg; Kymron deCesare; Donald P Land; Kent E Hutchison; Nolan C Kane
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.